SLC22A5 and cancer: In kidney cells, it was discovered that cisplatin can inhibit the plasma membrane carnitine transporter organic cation/carnitine transporter 2 (SLC22A5) (Lancaster et al., 2010), in agreement with the increase in plasma carnitine levels observed in cancer patients upon cisplatin treatment (Heuberger et al., 1998).